COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥1,011 | ¥965 | ¥828 | ¥755 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | ¥798 | ¥777 | ¥659 | ¥604 |
| Gross Profit | ¥213 | ¥188 | ¥169 | ¥151 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥152 | ¥139 | ¥123 | ¥108 |
| Sales & Mktg Exp. | ¥2 | ¥2 | ¥2 | ¥2 |
| Other Operating Expenses | ¥20 | ¥18 | ¥16 | ¥14 |
| Operating Expenses | ¥173 | ¥157 | ¥139 | ¥122 |
| Operating Income | ¥40 | ¥32 | ¥30 | ¥30 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | ¥2 | ¥2 | ¥3 | ¥3 |
| Pre-Tax Income | ¥42 | ¥34 | ¥33 | ¥33 |
| Tax Expense | ¥11 | ¥9 | ¥9 | ¥10 |
| Net Income | ¥31 | ¥24 | ¥24 | ¥23 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.85 | 308.61 | 300.48 | 292.37 |
| % Growth | 26.6% | 2.7% | 2.8% | – |
| EPS Diluted | 390.85 | 308.61 | 300.48 | 292.37 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥22 | ¥20 | ¥17 | ¥15 |
| EBITDA | ¥65 | ¥54 | ¥50 | ¥48 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |